In subsequent analyses, we demonstrated that HDAC inhibitors, BCL2 inhibitors and endocytosis/dynamin inhibitors sensitized primary resistant DLBCL cells to AD-O51.4. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.